Nucleai
Sector: Healthcare & Life Sciences
About Nucleai
Next-Gen Diagnostics AI-Driven Spatial Biomarkers
Products
ATOMS (Spatial AI Platform); Biomarker Discovery Services
The platform pioneers AI-driven spatial biomarker analysis, offering a multimodal solution. It ingests images from various modalities (H&E, IHC, multiplex immunofluorescence, and spatial transcriptomics), conducts advanced spatial analysis, and delivers actionable insights. These insights optimize biomarker scoring, determine biomarker prevalence and mechanism of action (MoA), and predict response to therapy, revolutionizing our approach to disease diagnosis and treatment.
Latest Company Updates
- Investment Reports: Interview with Avi Veidman
- Nucleai and University of Glasgow Partner to Pioneer Multimodal Precision Medicine for Colorectal Cancer
- AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients
- Top 10 Spatial Biology Companies of 2025
- Nucleai to Showcase Expanded Suite of ADC Biomarker Scoring Solutions at ASCO 2025